secwatch.observer — SEC 8-K summary
======================================

Issuer:     FibroBiologics, Inc. (FBLG)
CIK:        0001958777
Form:       8-K
Filed at:   2024-02-02T23:59:59+00:00
Accession:  0001493152-24-004643
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroBiologics begins trading on Nasdaq via direct listing under ticker FBLG
----------------------------------------------------------------------------

- Direct listing commenced January 31, 2024 on the Nasdaq Global Market.
- Stock trades under ticker symbol FBLG.
- Company is a clinical-stage biotech focused on fibroblast-based therapies for chronic diseases.
- Registration statement on Form S-1 declared effective by SEC on January 24, 2024.
- No financial results or operational milestones were disclosed in the announcement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1958777/000149315224004643/0001493152-24-004643-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1958777/000149315224004643/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-004643

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer